 | This article has multiple issues. Please help
improve it or discuss these issues on the
talk page. (
Learn how and when to remove these template messages)
|
 | |
| Clinical data | |
|---|---|
| Trade names | Spasmoctyl 40, Doralin |
| AHFS/ Drugs.com | International Drug Names |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard ( EPA) | |
| ECHA InfoCard | 100.043.128 |
| Chemical and physical data | |
| Formula | C29H43BrN2O4 |
| Molar mass | 563.577 g·mol−1 |
| 3D model ( JSmol) | |
| |
| |
 
(what is this?)
(verify) | |
Otilonium bromide, sold under the trade name Spasmomen among others, is an antimuscarinic and calcium channel blocker used to relieve spasmodic pain of the gut, especially in irritable bowel syndrome. [1] This means it works in the gut themselves, by relaxing the small muscles of the intestines, which results in relieving cramps and therefore reduces pain.
Medical uses
A pooled analysis of three clinical trials suggest that otilonium is more effective than placebo for the treatment of irritable bowel syndrome. [2]
Pharmacology
Otilinium binds to both muscarinic receptors and tachykinin NK2 receptors. [3] It has been shown to inhibit L-type and T-type calcium channels, actions which may contribute to or determine its effects in the gut. [4] [5]
When taken orally, very little of the drug is absorbed into the rest of the body, [6] which means that most of its actions remain confined to the gastrointestinal system.
References
- ^ "Dismox" (PDF). Archived from the original (PDF) on 4 March 2016.
- ^ Clavé P, Tack J (March 2017). "Efficacy of otilonium bromide in irritable bowel syndrome: a pooled analysis". Therapeutic Advances in Gastroenterology. 10 (3): 311–322. doi: 10.1177/1756283X16681708. PMC 5305018. PMID 28246548.
- ^ Evangelista S (1999). "Otilonium bromide: a selective spasmolytic for the gastrointestinal tract". The Journal of International Medical Research. 27 (5): 207–22. doi: 10.1177/030006059902700501. PMID 10689627.
- ^ Martin MT, Hove-Madsen L, Jimenez M (April 2004). "Otilonium bromide inhibits muscle contractions via L-type calcium channels in the rat colon". Neurogastroenterology and Motility. 16 (2): 175–83. doi: 10.1111/j.1365-2982.2004.00518.x. PMID 15086871. S2CID 7315438.
- ^ Strege PR, Sha L, Beyder A, Bernard CE, Perez-Reyes E, Evangelista S, et al. (May 2010). "T-type Ca(2+) channel modulation by otilonium bromide". American Journal of Physiology. Gastrointestinal and Liver Physiology. 298 (5): G706-13. doi: 10.1152/ajpgi.00437.2009. PMC 2867415. PMID 20203058.
- ^ Shin BS, Kim JJ, Kim J, Hu SK, Kim HJ, Hong SH, et al. (January 2008). "Oral bioavailability and enterohepatic recirculation of otilonium bromide in rats". Archives of Pharmacal Research. 31 (1): 117–24. doi: 10.1007/s12272-008-1129-2. PMID 18277617. S2CID 25727036.
 | This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
| This article has multiple issues. Please help
improve it or discuss these issues on the
talk page. (
Learn how and when to remove these template messages)
|
|
| |
| Clinical data | |
|---|---|
| Trade names | Spasmoctyl 40, Doralin |
| AHFS/ Drugs.com | International Drug Names |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard ( EPA) | |
| ECHA InfoCard | 100.043.128 |
| Chemical and physical data | |
| Formula | C29H43BrN2O4 |
| Molar mass | 563.577 g·mol−1 |
| 3D model ( JSmol) | |
| |
| |
|
(what is this?)
(verify) | |
Otilonium bromide, sold under the trade name Spasmomen among others, is an antimuscarinic and calcium channel blocker used to relieve spasmodic pain of the gut, especially in irritable bowel syndrome. [1] This means it works in the gut themselves, by relaxing the small muscles of the intestines, which results in relieving cramps and therefore reduces pain.
Medical uses
A pooled analysis of three clinical trials suggest that otilonium is more effective than placebo for the treatment of irritable bowel syndrome. [2]
Pharmacology
Otilinium binds to both muscarinic receptors and tachykinin NK2 receptors. [3] It has been shown to inhibit L-type and T-type calcium channels, actions which may contribute to or determine its effects in the gut. [4] [5]
When taken orally, very little of the drug is absorbed into the rest of the body, [6] which means that most of its actions remain confined to the gastrointestinal system.
References
- ^ "Dismox" (PDF). Archived from the original (PDF) on 4 March 2016.
- ^ Clavé P, Tack J (March 2017). "Efficacy of otilonium bromide in irritable bowel syndrome: a pooled analysis". Therapeutic Advances in Gastroenterology. 10 (3): 311–322. doi: 10.1177/1756283X16681708. PMC 5305018. PMID 28246548.
- ^ Evangelista S (1999). "Otilonium bromide: a selective spasmolytic for the gastrointestinal tract". The Journal of International Medical Research. 27 (5): 207–22. doi: 10.1177/030006059902700501. PMID 10689627.
- ^ Martin MT, Hove-Madsen L, Jimenez M (April 2004). "Otilonium bromide inhibits muscle contractions via L-type calcium channels in the rat colon". Neurogastroenterology and Motility. 16 (2): 175–83. doi: 10.1111/j.1365-2982.2004.00518.x. PMID 15086871. S2CID 7315438.
- ^ Strege PR, Sha L, Beyder A, Bernard CE, Perez-Reyes E, Evangelista S, et al. (May 2010). "T-type Ca(2+) channel modulation by otilonium bromide". American Journal of Physiology. Gastrointestinal and Liver Physiology. 298 (5): G706-13. doi: 10.1152/ajpgi.00437.2009. PMC 2867415. PMID 20203058.
- ^ Shin BS, Kim JJ, Kim J, Hu SK, Kim HJ, Hong SH, et al. (January 2008). "Oral bioavailability and enterohepatic recirculation of otilonium bromide in rats". Archives of Pharmacal Research. 31 (1): 117–24. doi: 10.1007/s12272-008-1129-2. PMID 18277617. S2CID 25727036.
|
| This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |